A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants (NCT07218770) | Clinical Trial Compass
Active — Not RecruitingPhase 1/2
A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
United States72 participantsStarted 2025-12-17
Plain-language summary
This study is researching an experimental drug called REGN7041 (also referred to as "study drug"). The study is focused on patients who have active inflammation inside of the eye without any signs of infection.
The aim of the study is to see how safe and tolerable the study drug is. This is the first time the study drug is being tested in humans.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug
* How much study drug is in the blood and the fluid in the eye at different times
* Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Diagnosis of non-infectious anterior, intermediate, posterior or panuveitis (For anterior uveitis, there must be evidence of inflammation affecting the posterior segment), as defined in the protocol
. Active disease at baseline, as defined in the protocol
. Part A only: Best Corrected Visual Acuity (BCVA) of ≤65 and \>10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of worse than or equal to 20/50 and better than 20/630) at the screening visit and on day 1
. Part B only: BCVA of \<75 and \>10 ETDRS letters (Snellen equivalent of worse than 20/32 and better than 20/630) at the screening visit and on day 1
Exclusion criteria
. BCVA of ≤30 ETDRS letters (Snellen equivalent of 20/250 or worse) at the screening visit and/or on day 1
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this is a Phase 1/2 trial of REGN7041, what does that early phase mean for what's currently known about its safety, and how does that compare to existing treatments for noninfectious uveitis affecting the posterior segment?
2The trial is actively enrolling but no longer recruiting new participants — does that mean there's any chance of joining a related study, or should we be focusing entirely on other treatment options right now?
3Given that the primary thing being measured is the occurrence of treatment-emergent adverse events, what kinds of side effects are researchers most concerned about watching for with REGN7041, and how might those affect my day-to-day life?
4Are there established standard-of-care treatments for posterior segment noninfectious uveitis that I should consider trying first, or would pursuing a study like this one be a reasonable path at my current stage of the disease?
5If I were ever eligible for a trial like this in the future, what would the monitoring and follow-up schedule look like, and is that level of commitment realistic given my work and personal situation?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Occurrence of Treatment-Emergent Adverse Events (TEAEs)